MedTrace Logo

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

NCT05371860 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-09-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the feasibility, based on recruitment rate over a 3-year period, of enrolling patients for the omission of post-operative breast radiation following breast conserving surgery and sentinel node biopsy or axillary lymph node dissection in women with HER2+ breast cancer who achieve pathologic complete response.

Conditions

Interventions

OTHER

Omit breast radiation

Omit breast radiation for 3 years after surgery

Sponsors & Collaborators

  • Armando Giuliano

    lead OTHER

Principal Investigators

  • Armando Giuliano, MD, FACS, FRCSEd · Cedars-Sinai Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-31
Primary Completion
2028-10-31
Completion
2028-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05371860 on ClinicalTrials.gov